SIRT3 and liver dysplastic nodule: In addition, new anti-inflammatory therapies and metabolic modulators, such as JAK/STAT, Rho-kinase and Sirtuin-3 inhibitors, peptide N-Acetyl-Seryl-Aspartyl-Proline, glycolysis inhibitors, and mineralocorticoid receptor antagonists, have been postulated as potential drugs in DN due to the preclinical evidence, showing their renoprotective role or even their ability to reverse established renal damage (Hashimoto et al., 2010; Bakris et al., 2020; Locatelli et al., 2020; Opazo-Ríos et al., 2020b; Srivastava et al., 2020; Matoba et al., 2021).